Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484678 | 0.90 | MEN1 (0.61) | MEN1KMT2AKCNH2SLC6A3HSD11B1 | |
| SCHEMBL27564901 | 0.90 | SIGMAR1 (0.73) | MEN1KMT2AKCNH2FAAHSIGMAR1 | |
| SCHEMBL27552111 | 0.89 | MEN1 (0.73) | MEN1KMT2AKCNH2SLC6A3HSD11B1 | |
| SCHEMBL27564818 | 0.88 | SIGMAR1 (0.76) | MEN1KMT2AKCNH2FAAHSIGMAR1 | |
| SCHEMBL17275260 | 0.86 | MEN1 (0.69) | MEN1KMT2AKCNH2SLC6A3HSD11B1 | |
| SCHEMBL5524549 | 0.86 | MEN1 (0.69) | MEN1KMT2AKCNH2SLC6A3HSD11B1 | |
| SCHEMBL16795428 | 0.86 | KCNH2 (0.56) | MEN1KMT2AKCNH2HSD11B1FAAH | |
| SCHEMBL5477755 | 0.86 | FAAH (0.57) | MEN1KMT2AKCNH2HSD11B1FAAH | |
| SCHEMBL9426415 | 0.85 | MEN1 (1.00) | MEN1KMT2AKCNH2POLBGAA | |
| SCHEMBL13149771 | 0.85 | MEN1 (0.68) | MEN1KMT2AKCNH2SLC6A3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | claimed |
| CN-102026975-A | Piperazines as anti-obesity agents | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | claimed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| WO-1996041802-A1 | NOVEL HETEROAROMATIC PIPERAZINES FOR USE AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-12-27 | — | — | WO | claimed |
| CN-102026975-A | Piperazines as anti-obesity agents | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| WO-1996041802-A1 | NOVEL HETEROAROMATIC PIPERAZINES FOR USE AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | MEN1 4682/4885KMT2A 3413/4885KCNH2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.